-
Video
The Inflation Reduction Act: Implications for Biopharma Companies and Patients
09.23.2022
See our webinar, featuring DLA Piper, on the Inflation Reduction Act healthcare provisions.
-
Statement
Incubate Statement on Amendment 5284 of the Inflation Reduction Act
08.06.2022
Incubate issued the following statement in response to amendment 5284 of the Inflation Reduction Act:
-
Article
US Government Poised for Long-Awaited Powers on Drug Pricing
08.06.2022
Via Bloomberg: Drugmakers have long said R&D will suffer if prices regulated
-
Article
HEALTH CARE BRIEFING: Senate Drug Measures Cut Deficit, CBO Says
08.04.2022
Via Bloomberg Government: Senate Democrats’ tax, climate, and drug-pricing bill would cut down federal budget deficits by $102 billion over 10 years, the nonpartisan Congressional Budget Office said.
-
Article
Biotech Investors Sound the Alarm on Senate Drug Pricing Bill
08.03.2022
Via the Washington Times: A group of biotech investors and doctors are warning that the Senate’s drug-pricing proposal, aimed at lowering skyrocketing prices, would “strike a huge blow” to patient access and halt research on new treatments for Alzheimer’s disease, heart disease and cancer.
-
Article
Don’t Look Up? Congress Can’t Ignore Risk to Small Molecule Drugs in Pricing Bill, Investors Warn
08.03.2022
A budget-neutral fix that would extend the time before small molecule drugs are subject negotiations but increase the minimum discounts for the products is floated as the pricing legislation moves toward a Senate floor vote.
-
Video
Incubate Investor Panel on the Senate’s Inflation Reduction Act of 2022
08.03.2022
Members of Incubate's network, Peter Kolchinsky, PhD, Managing Partner at RA Capital Management; JF Formela, MD, Partner at Atlas Venture; Guarav Gupta, MD, MS - Founder and Managing Partner, Ascendant BioCapital; and Duane Schulthess, Managing Director of Vital Transformation, speak on the impacts of the Inflation Reduction Act on the early-stage life science industry.
-
Statement
Incubate Letter on Reconciliation Drug Pricing Provisions
07.15.2022
Read Incubate's letter to the US Senate on their recent drug price provisions in the Reconciliation package
-
Statement
Incubate Statement on Federal Drug Price Provisions
07.06.2022
See Incubate's statement in response to the recent Reconciliation bill text on drug price controls.
-
Statement
Incubate Statement on WTO Decision to Suspend Global IP Rights
06.30.2022
The Incubate Coalition issued the following statement preceding the WTO TRIPS Council meeting (July 6-7) and following the World Trade Organization’s decision at its 12th Ministerial Conference in Geneva, Switzerland to waive intellectual property (IP) protections for Covid-19 vaccines.
-
Article
LTE: Patents protect people’s access to life-saving medicine
06.05.2022
See Incubate's letter to the editor about why patents are necessary in protecting patient access.
-
Statement
Incubate Comment in Response to the FTC’s Request for Comments on the Business Practices of PBMs
05.25.2022
Read Incubate's response to the FTC's Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers
Resources
